TLSA vs. CNTX, GRFS, LVTX, MYNZ, NLSP, PHVS, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Context Therapeutics (NASDAQ:CNTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.
Context Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 343.79%. Given Tiziana Life Sciences' higher probable upside, equities research analysts clearly believe Context Therapeutics is more favorable than Tiziana Life Sciences.
In the previous week, Context Therapeutics had 6 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for Context Therapeutics and 4 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.96 beat Context Therapeutics' score of 0.47 indicating that Context Therapeutics is being referred to more favorably in the media.
Context Therapeutics' return on equity of 0.00% beat Tiziana Life Sciences' return on equity.
Context Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
14.0% of Context Therapeutics shares are held by institutional investors. 9.4% of Context Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Tiziana Life Sciences received 84 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 63.16% of users gave Context Therapeutics an outperform vote.
Summary
Context Therapeutics and Tiziana Life Sciences tied by winning 6 of the 12 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Tiziana Life Sciences Competitors List
Related Companies and Tools